The dual action of binuclear silver(i) terpyridine complexes: anticancer and wound healing properties Authors: Mahmoud T. Abo-Elfadl, Mohamed I. A. Mohamed, Rabaa M. Khaled, Krzysztof Radacki, Gamal A. E. Mostafa, Essam A. Ali, Ola R. Shehab, Ahmed M. Mansour Published: 2026 ABSTRACT Reaction between 4′-(2-pyridyl)-2,2′:6′,2″-terpyridine (1) and silver(i) trifluoromethane sulfonate in methanol afforded the [Ag2(CF3SO3)2(1)2] (2). The dimeric structure of 2 was modified by the incorporation of a secondary ligand, including diphenyl pyridyl phosphine, 4,4′-bipyridine, and the antifungal agent clotrimazole, resulting in the formation of ternary complexes 4, 6, and 8, respectively. The silver(i) complexes were fully characterized using various analytical and spectroscopic techniques prior to the evaluation of their cytotoxicity against the malignant A375 and normal HDFn cell lines. Complexes 4 and 8 exhibited promising cytotoxicity against the A375 cell line with IC50 values of 3.06 ± 0.1 and 4.7 ± 0.5 µg mL−1, respectively. However, compared with the cancerous A375 cell line, the normal cell line HDFn was more responsive to the tested compounds we evaluated. Cell cycle analysis revealed distinct cell line dependent responses, with cell cycle arrest during S-phase in the HDFn cells and the G0-G1 phase in the A375 cells. The complexes markedly accelerated wound healing at relatively low doses, with complexes 4, 6, and 8 showing the fastest rates of cell migration. Molecularly, the compounds increased the levels of TGF-β1 and PDGF proteins. In parallel, complex 4 showed antibacterial activity intermediate between those of complexes 2/6 and 8 against all tested microorganisms. Introduction The process of wound healing begins when the skin is injured, whether by trauma, surgery, or chronic disease. In general, there are two types of wounds: acute and chronic. Trauma and/or surgery are among the causes of acute wounds.1 Through a natural tissue repair process, acute wounds that affect the epidermis and superficial dermis usually heal within three weeks. Burns caused by heat, radiation, and chemical reactions are the most serious acute injuries. They continue to be a significant obstacle for medical scientists as a result. On the other hand, physical trauma, burns, and penetrating injuries are just a few of the causes of chronic wounds. Chronic wounds, such as diabetic ulcers, are very common, particularly in patients with diabetes, who have impaired healing mechanisms and ongoing inflammation. Chronic wounds last for at least three months and often lead to complications such as infection and delayed healing. Wound healing occurs in two main stages: inflammation and cell proliferation.2 Sepsis generally makes wounds more vulnerable to bacterial infections.3 Bacterial infection impedes wound healing by delaying the inflammatory response and damaging the surrounding tissues.4 Cell proliferation, the migration of epithelial cells, and the formation of new tissue are all hindered by infection.5 In fact, bacterial cells and secretomes from different strains, both Gram-positive and Gram-negative, such as Staphylococcus aureus and Pseudomonas aeruginosa, hinder epithelial cell motility.6 As a result, finding efficient, and timely methods for managing wound care remains a top priority for the medical community. It is of significant interest to develop novel materials with antibacterial and anti-inflammatory properties that activate and promote cell epithelialization. In general, wound dressings have become a particularly successful therapeutic approach among the various methods of wound treatment.7 Exudate absorption, hydration maintenance, microbiological prevention, and biocompatibility are just a few of the critical areas where advanced wound dressings shine.8,9 On a molecular level, several proteins are essential for the skin-healing process. The transforming growth factor-β (TGF-β) is a key regulator of skin morphogenesis. It plays an essential role in epidermal formation, stratification, and cell differentiation.10 Another important molecular mechanism involved in skin healing is neovascularization. Adequate blood supply is an indispensable for wound healing. Platelet-derived growth factor (PDGF) plays a role in almost all stages of skin healing, including angiogenesis and fibroblast proliferation. PDGF gel has been previously approved by the FDA for the treatment of diabetic ulcers.11 One of the main reasons why wounds take longer to heal is infection.12 As a result, infection control should be carefully considered when managing wounds. An aseptic approach, adequate debridement, and suitable antimicrobial treatments should be used to treat wounds in order to prevent infection.13 The use of noble-metal antimicrobials, the most common of which is silver(i), is one tactic receiving increased attention for reducing wound sepsis and preventing bacterial infection.4,14 Silver-releasing dressings are used to keep the wound free of microorganisms, allowing it to heal. Due to their antibacterial, antiseptic, and anti-inflammatory properties, as well as their minimal human toxicity,15,16 silver(i) ions can be utilized in therapeutic agents, wound dressings, and regenerative medicine.17 By interfering with enzymes that bind Ag(i) ions to the cell wall or by withdrawing electrons from these biological components, silver(i) ions can kill bacteria by penetrating their cells and destroying cellular integrity and permeability.18 For example, until a few years ago, silver(i) nitrate, also known as the Crede method, was widely used to treat ophthalmia neonatorum.19 For a long time, a diluted silver(i) nitrate solution was applied to newborns' eyes to prevent gonorrhoea infection transmitted from the mother.17 As silver(i) nitrate immediately precipitates as silver(i) chloride under physiological conditions, its use as an antimicrobial agent is limited. Therefore, a higher dose is required since most of the Ag(i) ions do not reach the infected site. In 1968, Fox recommended silver(i) sulfadiazine as the active ingredient in a topical treatment for Pseudomonas infections associated with burn wounds.20,21 Initial research showed that silver(i) sulfadiazine acts as a prodrug by gradually releasing the biologically active silver(i) ions into the wound site. When interacting with the biological components, silver(i) sulfadiazine showed the highest rate of silver(i) release compared with other silver(i) complexes; after 40 h of reaction with serum, 20% of the silver(i) complex remained undissociated.22,23 Argyria, particularly after extended exposure, neurotoxicity, renal and hepatic toxicity, and leukopenia are among the adverse outcomes that have been documented following treatment with silver(i) sulfadiazine; however, the latter has been disputed as a result of the burn wound itself.24 Details about the toxicity of silver(i) sulfadiazine and its adverse effects have been examined elsewhere.25,26 Research into the synthesis of silver(i) compounds with enhanced antibacterial activity has increased due to the disadvantages of silver(i) sulfadiazine and other drugs, especially against drug-resistant bacteria. In addition, recent studies have highlighted silver(i) complexes as promising anticancer agents with significant activity against a broad range of tumour cells. Reviews have emphasized that advances in ligand design and structure–activity relationship studies have accelerated their development as metallodrugs.15,27,28 Early investigations indicate that the biological activity of silver(i) complexes can be tuned through ligand selection, making them attractive candidates for the development of novel anticancer therapeutics with mechanisms distinct from those of conventional platinum drugs. In the field of coordination chemistry, the variable coordination number of Ag(i) and its ability to generate diverse geometries with fascinating structural properties have received significant attention.29–32 In general, 2,2′:6′,2″-terpyridine has a unique ability to coordinate with diverse metal ions, hence its coordination behaviour with silver(i) ions is interesting due to its varied coordination modes, photophysical properties, and diverse applications.33–43 In particular, terpyridine ligands functionalized with the fourth pyridine ring, such as 4′-(3-pyridyl)-2,2':6′,2″-terpyridine (3-py-tpy) and 4′-(2-pyridyl)-2,2':6′,2″-terpyridine (2-py-tpy), exhibited distinct architectures with Ag(i) ions that differed depending on the reaction conditions and the type of the silver(i) counterion.39,40,42,43 For instance, Dehnen synthesised three one-dimensional coordination polymers from [Ag(NO3)(3-py-tpy)], wherein Ag(i) is coordinated by four nitrogen atoms from a tridentate ligand and one nitrogen atom from the terminal pyridine ring (Fig. 1a).39 The reaction between 2-py-tpy and silver(i) salt yielded a mixture of dinuclear complexes, wherein the metal centre exhibits four- and five-coordinate modes, completed by PF6− in the coordination sphere (Fig. 1b).40 Recrystallization of the silver(i) complex of 2-py-tpy bearing a triflate counterion in acetonitrile (Fig. 1c) yielded a five-coordinate dinuclear complex composed of a tridentate ligand, an acetonitrile molecule, and the terminal pyridyl nitrogen of the second molecule.42 A dinuclear complex was produced (Fig. 1d) when 2-py-tpy and silver(i) trifluoroacetate reacted.39 The four-coordinate silver(i) ions in this compound are bound by two terpyridine ligands and a trifluoroacetate ion. Structures of some of the previously published silver(i) terpyridine complexes (a–d) coordinated by 4′-(3-pyridyl)-2,2':6′,2″-terpyridine (3-py-tpy) and 4′-(2-pyridyl)-2,2':6′,2″-terpyridine (2-py-tpy) ligands. Using a variety of analytical and spectroscopic techniques, the chemistry of novel stable silver(i) complexes functionalized with the 2-py-tpy ligand (1) as a primary ligand (Scheme 1) is thoroughly examined and addressed in this work. We anticipated that adding a pyridine group to the 4′-position of the terpyridyl framework would cause the pyridine N atom from a neighbouring molecule to coordinate with the metal centre, creating at least a dimeric structure as in complex 2 (Scheme 1).42,43 For the first time, the dimeric structure of this class of Ag(i) terpyridine complexes was altered by the addition of a secondary ligand with important properties. As shown in Scheme 1, diphenyl pyridyl phosphine (PPh2Py), 4,4′-bipyridine (bpy4,4′), and clotrimazole (CTZ), an antifungal drug, were added to the coordination sphere of the dimeric silver(i) complex 2. Herein, PPh2Py has been utilized as a secondary ligand since heterobifunctional phosphines with “hard” N and “soft” P atoms have received special attention.44,45 Interesting features of this P,N-system include stereo-electronic control of metal centres, reversible dissociation of weak M–L bonds, and preferential binding to soft and hard metal ions.46 Our earlier research on PPh2Py Ru(ii) complexes showed potent effects on a leukaemia cell line.47 A literature review found that little work has been reported on the chemistry and cytotoxicity of silver(i) terpyridine containing the PPh2Py ligand.48 On the other hand, 4,4′-bipyridine was employed as a secondary ligand to produce a polymeric complex (see 6 in Scheme 1) with distinct characteristics for wound healing and wound dressings from the dimeric structure.49 Synthesis of silver(i) terpyridine complexes functionalized with secondary ligands; diphenyl pyridyl phosphine (PPh2Py) (4), 4,4′-bipyridine (bpy4,4′) (6), and the antifungal drug clotrimazole (8). In addition to creating entirely novel metal-based lead structures to address unique biological applications such as wound healing and wound dressings, current strategies also rely on coordinating known medications and drug candidates with inert metal-based fragments.50–52 This approach raises the intriguing question of how metal binding will alter the drug's biological activity and whether synergistic effects can be achieved in this manner. Azole-based medications are promising in this regard; they have been investigated for several decades in antifungal chemotherapy.53 To address this matter, we modified complex 2 by adding the antifungal drug, clotrimazole to the complex's coordination sphere (see 8 in Scheme 1). The silver(i) complexes were fully characterized using a variety of analytical and spectroscopic tools. The hydrophilic character of the silver(i) complexes and their stability under physiological conditions with and without chloride ions were ascertained. Next, their cytotoxicity and safe doses were assessed against the human epithelial skin malignant melanoma cell line, A375, and the dermal fibroblast normal human neonate cell line, HDFn. Flow cytometry was used to assess the effect of the complexes on the cell cycle and to examine their impact on DNA replication and division. As a cornerstone of skin healing, we performed a scratch assay to assess the potential of the tested compounds, at their safe doses, to promote cell migration and heal open wounds. At the molecular level, the cell proliferation marker, TGF-β, was visualized by immunofluorescence microscopy, and the vascularization marker, PDGF, was quantified by sandwich ELISA. Finally, the antimicrobial effects of the compounds were evaluated against different bacterial strains. Results and discussion Synthesis and characterization 2-Pyridinecarboxaldehyde reacted with two equivalents of 2-acetylpyridine in the presence of both potassium tert-butoxide and ammonia solution affording 4′-(2-pyridyl)-2,2':6′,2″-terpyridine (L) (1, Scheme 1) in a good yield and high purity.54 A white precipitate 2 (Scheme 1) was produced when 1 and silver(i) trifluoromethane sulfonate reacted in methanol; the crystal structure of this precipitate [Ag2L2(CF3SO3)2] was previously reported.43 As shown Scheme 1, each pair of molecules of 2 forms a pocket structure via head-to-tail interactions. In other words, silver(i) terpyridyl units are linked by Ag–N bonds of the terminal pyridyl ring forming a dimeric structure in a five-coordinate mode that is completed by a triflate ion.43 We had previously discovered another crystal structure (Fig. 1c) of 2 in which two acetonitrile molecules replaced the two triflate ions.42 Moreover, we previously presented an NMR analysis-based confirmation (Fig. S1) that, in the case of methanol and acetonitrile, the dinuclear structure is maintained in solution; but, in the case of strong coordinating solvents such as DMSO, the mononuclear analogue ([AgL(DMSO)]·CF3SO3) is produced.42 The 1H NMR spectrum (Fig. S1) of 2, in DMSO-d6, clearly shows the coordinated DMSO-d6 signal. The presence of two acetonitrile molecules in the coordination sphere of 2, in the form of [Ag2L2(CH3CN)2]·2(CF3SO3), inspired us to replace them out for secondary ligands like diphenyl pyridyl phosphine, 4,4′-bipyridine, and clotrimazole in an effort to identify compounds with interesting properties for therapeutic applications and wound dressings. When the secondary ligands (3, 5, and 7; Scheme 1) were added to suspensions of 2 in methanol, clear solutions resulted from the formation of our ternary complexes (4, 6, and 8; Scheme 1), respectively. The solutions of 4, 6, and 8 were filtered and left to stand. The solvent progressively evaporates, giving pale yellow precipitates. The novel ternary complexes were structurally elucidated by 1H NMR (Fig. S2–S4), 13C NMR (Fig. S5–S7), IR (Fig. S8), positive mode electrospray ionization mass spectrometry (Fig. S9–S11), as well as elemental analysis. In the case of diphenyl pyridyl phosphine (Fig. S2), and 4,4′-bipyridine (Fig. S3), the ratio of the signals of the terpyridine ligand to those of the secondary ligand is 1 : 1, while in the case of clotrimazole (Fig. S4), it is 2 : 1, as demonstrated by the integrations of the 1H NMR signals of the complexes. Unlike 2, it is also evident that the presence of a secondary ligand gives the ternary complexes in DMSO-d6 an additional stability and maintains their dinuclear structure in the solution. For instance, we were unable to detect the 1H NMR signal of the coordinated solvent in the solutions of the ternary complexes. PPh2Py is a flexible ligand that can form a range of homo- and heteronuclear complexes by binding metal ions via one coordination site (κ1P or κ1N), two sites (κ2P,N), or as a bridging ligand.47,55 When comparing the NMR spectra of PPh2Py (Fig. S12) and 4, the resonance of the H6 proton changed only by 0.06 ppm, ruling out the coordination of pyridine ring to the metal ion. This may be taken as evdience that PPh2Py ligand coordinated Ag(i) as a κ1P monodentate ligand. The analysis of 4 by 31P NMR (Fig. S13) and comparison of its 31P signal with that of the free PPh2Py ligand have further validated this. In the free PPh2Py, the 31P NMR signal appears at −3.87 ppm, however upon coordination to an Ag(i) ion, a multiplet signal is observed at 13.11 ppm, attributed to the donation of the lone pair from the phosphorus atom and the resultant deshielding effect. The 19F NMR signal (Fig. S14) of the triflate ion appears at −81.17 ppm. Following the interaction of the PPh2Py ligand with the dinuclear system, the 31P NMR remains unaltered (Fig. S12). Comparison of the IR spectra of the free ligand and the Ag(i) complexes (Fig. S8) reveals a diagnostic shift of the pyridyl v(C Created by potrace 1.16, written by Peter Selinger 2001-2019 N)/ν(CC) stretching band from 1602 cm−1 to 1590–1593 cm−1 upon coordination.56 This red shift is consistent with electron donation from the pyridine nitrogen atoms to the silver(i) center and provides compelling spectroscopic evidence for the involvement of the pyridyl donors in metal binding. The mass spectra (Fig. S9–S11) of 4, 6, and 8 show mainly peaks corresponding to {L + H}+, {L + Na}+, {AgL}+, and {2L + Na}+ at m/z = 311.4, 333.3, 417.2, and 643.4 in that order. In the mass spectrum of 4, a distinct peak corresponding to {AgL(PPh2Py)}+ is found at m/z = 681.3. Despite extensive crystallization screening using various solvent systems and crystal-growth methods, suitable single crystals for X-ray diffraction analysis could not be obtained. Therefore, the proposed coordination modes of 1 towards the metal ions were assigned based on other spectroscopic techniques. Stability and partition coefficient determination Prior to assessing their potential cytotoxicity against a variety of malignant and normal cell lines, as well as their wound-healing potential, we used UV/vis spectrophotometry to examine the stabilities of the DMSO and DMSO-H2O solutions of 2, 4, 6, and 8 in the presence and absence of sodium chloride for 19 h. The wavelengths of the main bands did not change compared with their corresponding bands in DMSO when water was added to the medium up to 70% water content (for 2, 4 and 6) or 50% (for 8) (Fig. S15–S17). The obtained spectra of 2, 4, 6, and 8 in both media (DMSO and DMSO-water) as a function of time were nearly superimposable, suggesting a high stability. In general, the n-octanol/water partition coefficient can be used to measure the hydrophilic nature of the tested compounds, their potential for partitioning between phases, and even pharmacokinetic characteristics in biological systems. To correlate the lipophilicity of our complexes and their cytotoxicity (vide infra), we determined their partition coefficients (log D7.4) by the shake-flask method.57 According to Lipinski's58,59 “rule of 5”, which is based on molecular mass, lipophilicity, and the number and strength of hydrogen-bond donors and acceptors, a potential drug candidate should have a log D7.4 < 5. For hydrophilic compounds, log D7.4 values are generally negative; for lipophilic molecules, they are usually positive. The partition coefficient values for 2, 4, 6, and 8 were found to be 1.45 ± 0.02, 1.47 ± 0.10, 1.36 ± 0.06, and 1.48 ± 0.08, respectively, indicating that all of the investigated complexes are lipophilic with no discernible variations between them. Cell proliferation assay The cytotoxic efficacy of silver(i) terpyridine complexes against various cancer cell lines has been demonstrated.60,61 The cytotoxicity and safe doses of compounds 1–8 were assessed using the MTT assay against the human malignant melanoma cell line A375 and the primary human neonatal dermal fibroblast cell line HDFn. The cell lines were obtained from the American Type Cell Culture Bank (ATCC). After treating the normal and malignant cells with compounds 1–8 at serial dilutions ranging from 3.125 to 100 µg mL−1, the cells were incubated for 24 h. For every compound tested, the concentration (IC50 value ± SD) (Fig. S18) required to inhibit cell growth by 50% was determined (Table 1). All investigated compounds exhibited moderate to strong cytotoxicity against both studied cell lines, as shown in Table 1. When complex 2 is formed, the cytotoxicity increases by about 4300% compared to that of the terpyridine ligand; consequently, the IC50 value drops from 281.03 ± 17.74 to 6.37 ± 0.53 µM. Coordination of PPh2Py, 4,4′-bipyridine, and clotrimazole to form complexes 4, 6, and 8 modulated the cytotoxic activity relative to complex 2. Complexes 4 and 8 exhibited markedly enhanced cytotoxicity, with IC50 values of 1.84 ± 0.06 and 3.18 ± 0.34 µM, respectively, whereas complex 6 displayed comparable activity (IC50 = 6.31 ± 0.49 µM) to that of 2 (IC50 = 6.37 ± 0.53 µM). Furthermore, coordination of clotrimazole to form complex 8 significantly enhanced its cytotoxic activity, reducing the IC50 value from 26.08 ± 2.62 µM for the free drug to 4.70 ± 0.50 µM. Similar findings were observed for the normal HDFn cell line. Compared to the malignant cell line A375, complexes 2, 4, 6, and 8 had IC50 values of 2.52 ± 0.09, 0.61 ± 0.05, 2.18 ± 0.14, and 1.99 ± 0.20 µM, respectively, making them more potent against normal cells. Table 1The IC50 (µM) of 1–8 on both cell lines obtained by MTT assay after the incubation period of 24 ha,bCell line12345678A375281.03 ± 17.746.37 ± 0.53209.20 ± 15.971.84 ± 0.06383.96 ± 20.496.31 ± 0.4926.08 ± 2.623.18 ± 0.34HDFn292.58 ± 20.652.52 ± 0.09319.62 ± 20.530.61 ± 0.05447.53 ± 45.462.18 ± 0.1421.83 ± 1.451.99 ± 0.20Selectively index (SI)c1.040.401.530.331.170.350.840.63aEvery concentration was done in triplicate over the two iterations of the experiment. Data are represented as mean ± SD.bThe untreated cells served as the negative control.cSelectivity index (SI) was calculated as SI = IC50(HDFn)/IC50(A375). Values greater than 1 indicate preferential cytotoxicity toward A375 melanoma cells relative to normal HDFn fibroblasts. The IC50 (µM) of 1–8 on both cell lines obtained by MTT assay after the incubation period of 24 ha,b Every concentration was done in triplicate over the two iterations of the experiment. Data are represented as mean ± SD. The untreated cells served as the negative control. Selectivity index (SI) was calculated as SI = IC50(HDFn)/IC50(A375). Values greater than 1 indicate preferential cytotoxicity toward A375 melanoma cells relative to normal HDFn fibroblasts. As shown in Table 1, the selectivity analysis revealed notable differences among the compounds. Compounds 1, 3, and 5 exhibited preferential activity toward A375 melanoma cells over normal HDFn fibroblasts, with compound 3 showing the highest selectivity (SI = 1.53), followed by compounds 1 (SI = 1.04) and 5 (SI = 1.17). In contrast, compounds 2, 4, and 6–8 displayed SI values below unity, indicating limited tumour selectivity and a greater cytotoxic effect on normal cells. The antiproliferative activity of the present silver(i) terpyridine complexes compares favourably with that of previously reported silver(i) terpyridine derivatives.62,63 In particular, compounds 4 (IC50 = 1.84 ± 0.06 µM) and 8 (IC50 = 3.18 ± 0.34 µM) exhibited potent activity against A375 melanoma cells within the low-micromolar range, similar to the cytotoxicity reported for structurally related silver(i) terpyridine complexes against human breast adenocarcinoma (MCF-7), human lung adenocarcinoma (A549) and human esophageal squamous cell carcinoma (Eca-109) cancer cell lines (IC50 = 1.83–2.96 µM). These findings further underscore the capacity of terpyridine ligands to enhance the anticancer efficacy of silver(i) ions and support the continued development of silver(i) terpyridine scaffolds as promising metallodrug candidates. Finally, the cytotoxicity data obtained for both malignant and normal cell lines provide valuable insight into the therapeutic window of these complexes. The tested compounds can be administered at different dose levels to achieve therapeutic levels that affect malignant cells, or they can be selectively delivered to cancerous skin lesions to improve targeting. Cell cycle The interruption of the cell cycle sequence, which results in unchecked cell growth and excessive proliferation, is a major factor in the genesis and spread of cancer.64 A change in cell division during the stages of mitotic division compared to untreated samples is the first sign that the tested compound is interfering with cellular functions. These findings provide a basis for selecting the focus of future studies, even though several mechanisms may lead to cell accumulation at a specific stage of the cell cycle. Considering their inhibitory effect on cell growth, the effects of 2, 4, 6, 7, and 8 on the cell cycle of both A375 and HDFn cell lines were examined (Fig. 2 and Table 2). In the A375 cell line, we found that all the compounds significantly arrested the cell cycle at the G0–G1 phase compared with their respective controls, except for 7 (free clotrimazole) (Fig. S19). This drug inhibits the cell cycle at the G1-S phase transition.65 Furthermore, we observed that the complexes functionalized with 4,4′-bipyridine (6) and clotrimazole (8) produced a noticeably larger G0–G1 cell arrest. This is entirely different from the effects of other silver(i) terpyridine complexes on hepatocellular carcinoma cells (HepG2),60 where the complexes caused cell cycle arrest in the S-phase. However, it is comparable to the effect of certain silver(i) complexes on malignant melanoma cells (HTB-65).61 The One-way ANOVA followed by Tukey's multiple comparisons at a 95% confidence interval of the cell cycle phase distribution in A375 and HDFn cells after 24 h of application of 2, 4, and 6–8, in addition to the respective controls. (a) A comparison between the effects of all compounds in each cell cycle phase in each cell line showed a significant cell cycle arrest in the G0–G1 phase in the A375 cell line, while they were arrested in the S-phase in the HDFn cell line. (b) A comparison between the effects of each compound in the two cell lines showed that compound 2 arrested cells in the G0–G1 phase in the HDFn cell line more than in the A375 cell line, opposite to the effect of 4. Compounds 4 and 8 arrested cells in S-phase in the HDFn cell line more than in the A375 cell line, unlike 7. *p < 0.05, **p < 0.01, ***p < 0.001, ns p > 0.05. Table 2The 2-way ANOVA results followed by Tukey's multiple comparisons at a 95% confidence interval at each cell cycle phaseaG0/G1-phasesS-phaseTukey's multiple comparisons testA375HDFnTukey's multiple comparisons testA375HDFnSummary adjusted p valueSummary adjusted p valueControl vs.2***<0.001Control vs.2***<0.001***<0.001Control vs.4***<0.001Control vs.4Control vs.6Control vs.6Control vs.7Control vs.7Control vs.8Control vs.82vs.42vs.42vs.62vs.6**<0.0032vs.72vs.7***<0.001***<0.0012vs.82vs.84vs.64vs.64vs.74vs.7***<0.0014vs.84vs.86vs.7**<0.0066vs.7***<0.0017vs.8**<0.0057vs.8***<0.001aFor G2-M, all the relations are nonsignificant, >0.05. The 2-way ANOVA results followed by Tukey's multiple comparisons at a 95% confidence interval at each cell cycle phasea For G2-M, all the relations are nonsignificant, >0.05. In the case of the HDFn cell line (Fig. S20), all compounds and their control showed similar distributions in the G0–G1 phase, except for 4. The cell cycle arrest shifted to the S-phase, with a notable rise in 4. Compounds 6–8 significantly arrested the HDFn cell cycle in the S-phase more than both the control and 2, but less than 4. A comparison of the effects of each compound on the phases of the cell cycle in both cell lines (Fig. 2b) revealed that only 2 significantly arrested cells in the G0–G1 phase in the HDFn cell line, to a greater extent than in the A375 cell line, whereas compound 4 had the opposite effect. Complexes 4 and 8 substantially arrested HDFn cells in the S-phase more than A375 cells, whereas compound 7 had the opposite effect. Wound healing and cell migration by the scratch assay Re-epithelialization is the most crucial step in wound healing. To close the skin opening, cells move from the wound's edges toward the centre of the wound during this procedure.66 The basis of the in vitro scratch wound assay is the formation of a artificial gap (referred to as a “scratch”) in a complete cell monolayer. Typically, the cells tend to migrate and proliferate in order to heal the wound.67 The effect of our compounds, at their safe doses, on improving cell proliferation and migration to close the artificial scratches in both cell lines was evaluated by measuring the distances covered and the migration rate at 0, 6, and 24 hours until complete closure. In general, compounds 2, 4, and 6–8 considerably promoted wound healing in both normal and malignant cell lines at very low and non-toxic doses when compared to the control cells (Fig. S21 and S22). Using a 2-way ANOVA and Tukey's multiple comparisons test with a 95% confidence interval in the A375 cell line (Tables S1 and S2), we found that all compounds considerably improved wound closure compared to the control cells. Except for 8, compounds 4, 6, and 7 greatly improved wound closure compared to 2 after 6 h and continued to do so at 24 h. On the other hand, after just 6 h and continuing up 24 h, 4, and 6–8, considerably outperformed the control and 2 in promoting wound repair in HDFn cells. Moreover, after 24 h, the silver(i) complexes functionalized with 4,4′-bipyridine and clotrimazole, as well as the free drug 6–8, were noticeably superior to 2 and 4 (Fig. 3 and 4). The rate of cell migration and the wound healing closure % of A375 and HDFn cells after application of 2, 4, and 6–8 measured after 0, 6, and 24 h. The rate exceeds 10 µm h−1 after 6 h in 4, and 6–8, and 15 µm h−1 in 2, 4, 6, and 7 in the A375 cell line. In the HDFn cell line, the rate exceeds 10 µm h−1 after 6 h in 2, 4, 6, and 7, and up to 20 µm h−1 for 6 and 7 after 24 h. The closure % was close to 100% after 24 h in 4, and 6–8 in both cell lines, which was higher than the respective controls. The 2-way ANOVA comparisons of wound healing closure percentage of 2, 4, 6, and 7 on both HDFn and A375 cell lines. Only compound 2 significantly enhanced HDFn cells compared with A375 cells. Compounds 4, 6, and 7 enhanced HDFn cells more than they did in A375 cells. *p < 0.05, ***p < 0.001, ns non-significant. In comparison, compounds 4 and 6–8 demonstrated improved wound healing in HDFn cells compared with the malignant A375 cells, as assessed for each complex in both cell lines. However, the two cell lines showed similar responses after 24 h. The most interesting observation is the compounds' activity after only 6 h. In the A375 cell line, compounds 4 and 6–8 showed an enhanced rate of cell migration that exceeded 10 µm h−1 after the first 6 h. The high rate persisted up to 24 h for compounds 2, 4, 6, and 7, and reached 15 µm h−1. The percentage wound closure was almost 100% after 24 h of treatment with compounds 4, 6, and 7. In the normal fibroblasts (HDFn), the same observation was made after 6 h for compounds 4 and 6–8, with a much faster cell migration rate, exceeding 10 µm h−1, and 15 µm h−1 for compound 7. The percentage wound closure also reached nearly 100% in 6 and 7 after 24 h. Upon studying the compounds' behavior in both cell lines, it was clear that after 6 h, compounds 4, 6, and 7 significantly enhanced wound closure in the HDFn cell line compared with the A375 cell line, unlike compound 2. After 24 h, there was no significant difference in wound closure between the two cell lines for any of the compounds. The cell proliferative protein TGFβ-1 was highly enhanced by the tested compounds The process of wound healing is a multifaceted biological phenomenon that necessitates cellular interactions among various cell types, including fibroblasts, myofibroblasts, smooth muscle cells, endothelial cells, keratinocytes, and immune cells. Growth factors, hormones, blood components, and second messengers all play a role in regulating these interactions.68 Many growth factors, such as transforming growth factor-beta (TGF-β), are involved in wound healing, and throughout this process, the expression of their receptors changes.69,70 TGF-β is a multifunctional growth factor that is released by a range of cells, stimulates or inhibits cell proliferation, and plays a crucial role in the development of fibrosis. TGF-β increases the amount of collagen and fibronectin that fibroblasts produce and incorporate into the extracellular matrix. Moreover, TGF-β influences the proliferation and gene expression of all main cell types involved in wound healing.71 Haematopoietic cells primarily release TGF-β1, the main isoform of the TGF-β family, which has been demonstrated to have pleiotropic effects on a range of biological processes, including inflammation, tissue regeneration, immunological responses, fibrosis, and carcinogenesis.72 In the present contribution, compounds 2, 4, and 6–8 were administered to the A375 and HDFn cells at half of their IC50 values. Immunofluorescence microscopy was used to evaluate the expression of the TGF-β1 protein in A375 (Fig. 5) and HDFn cell lines. As Fig. 6 illustrates, the diphenyl pyridyl phosphine complex (4) greatly increased protein expression in both cell lines compared to both the control and the other compounds. Numerous studies have demonstrated that Ag(i) phosphine complexes belonging to the same family inhibit the growth of cancer cells and cause apoptosis in a variety of malignant cell lines.73–75 The immunofluorescence photos of TGF-β protein expression after application of 2, 4, and 6–8 in comparison to the control cells in (a) the A375 cell line with high expression in 4 and 6 and to a lesser extent in 2 and 8. (b) The HDFn cell line with high expression in 4, 6, and 8, and to a lesser extent in 2 and 7. The magnification is 40X, and the scale bar is 50 µm. The one-way ANOVA analysis of the TGF-β protein expression in the A375 and HDFn cell lines treated with 2, 4 and 6–8. In both cell lines, 4 showed the highest significant expression compared to the control and other compounds, followed by 6, 2, and 8. The data are normalized to the control and represented as mean ± SD. Columns with the same letters are not significantly different. Although not as much as 4, the 4,4′-bipyridine complex 6 also increased protein expression in both cell lines more than 2 and the clotrimazole complex 8. The free clotrimazole drug (7), did not significantly alter the amount of the protein expression in the A375 cell line when compared to the control, but it did so in the normal cell line. In other words, it is evident that the protein expression was greatly enhanced in both malignant and normal cell lines when the free drug was coordinated with the dinuclear silver(i) complex. Complex 8, produced more protein in the HDFn cell line than in the A375, but it did not differ much from the 4,4′-bipyridine complex, 6. The silver(i) complexes enhance vascularization through increased PDGF protein expression Physiologically, the platelet-derived growth factor (PDGF) can promote angiogenesis and wound repair by stimulating cell chemotaxis, proliferation, and division. The subunit PDGFA is necessary for normal skin morphogenesis, angiogenesis, and blood vessel development.76 Myofibroblasts must contract the wound in order for it to heal quickly. Thus, myofibroblast differentiation, which is primarily dependent on high PDGF production, initiates appropriate and optimal wound healing.77 Silver(i) complexes and nanoparticles have recently demonstrated their potential in wound and burn healing via the PDGF axis.78 Using the sandwich ELISA method,79 PDGF levels were measured in the cell lysates of the A375 and HDFn cell lines following a 24 h of treatment with compounds 2, 4, and 6–8. Compounds 4 and 6 considerably increased PDGF levels in the A375 cell line, surpassing both the control cells and the other compounds (Fig. 7). Complexes 2 and 8 also increased PDGF levels relative to the control cells. Although compound 7, the free clotrimazole drug, enhanced the PDGF level, it was not significantly different from the control cells. On the other hand, the most prominent compounds in the case of HDFn were 2 and 8, followed by 6. Compound 2 was the only compound that produced PDGF levels significantly higher than those of the control cells. Compound 7 and the control group were not different from each other. The PDGF-BB protein detection in the A375 and HDFn cell lines, which were treated with 2, 4, and 6–8. In the A375 cell line, compound 4 has the highest significant level of the protein compared to all other compounds and the control, except for 6. Compounds 2 and 8 are significantly higher than 7 and the control, but with no difference between each other. In the HDFn cell line, the leading was to compound 8 with no difference with 4. Compound 6 was significantly higher than 2, 7, and the control. There was no significant difference between 7 and the control. The data are represented as mean ± SD. Columns with the same letters are not significantly different. Antimicrobial properties There must be no overproduction or overgrowth of bacteria or fungi for wounds to heal and re-epithelize properly. If present, infection can lead to ulceration, especially in unfavourable conditions such as diabetes. Hence, the antimicrobial potential of the skin-healing agents is considered a significant advantage for these compounds. Silver(i)-containing compounds are well known for their antibacterial activity, even though there are approved skin-hydrogel products with silver(i) derivatives as antibacterial agents.80Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis and Micrococcus luteus, which are Gram-positive bacteria, along with one Gram-negative bacterium, Pseudomonas aeruginosa, were employed to evaluate the antibacterial properties of 2 and 6–8, while Candida albicans was utilised to assess their antifungal activity. The susceptibility of the treated microbial strains was evaluated using standard broth microdilution tests.81 The maximum inhibition zone was observed for compound 8 against all microorganisms. Stanković and co-workers reported similar behaviour in which clotrimazole's antifungal effectiveness was enhanced upon the coordination with silver(i) ions.82 Furthermore, the antibacterial activity of the diphenyl pyridyl phosphine complex 4 was lower than that of the clotrimazole complex and higher than that of the parent silver(i) complex 2 and the bipyridine analogue against every tested microorganism. Conclusions In this study, We were focused on skin lesions by synthesizing a novel class of dinuclear ternary Ag(i) terpyridine complexes with great potential for wound healing and the treatment of chronic ulcers in healthy skin tissues, as well as for prospective cancer therapies. The complexes are functionalized with distinctive secondary ligands including diphenyl pyridyl phosphine, 4,4′-bipyridine, and the antifungal agent clotrimazole. The solutions of the complexes are stable under physiological conditions. The silver(i) complexes show considerable wound-healing activity and increased cytotoxicity, but their selectivity is limited because they are more harmful to normal HDFn cells. Results from the cell-cycle and viability assays are consistent, demonstrating more potent cytotoxic effects and greater cell-cycle arrest in normal cells. The complexes and the free clotrimazole drug significantly increase cell migration at non-toxic dosages and accomplish nearly full wound closure in 24 h, with especially quick effects seen in HDFn cells. Rapid wound closure was attributed to increased cell migration rather enhanced proliferation.83 As has been previously demonstrated for the effects of low-dose cisplatin on bone cells, the results were determined by the dose and the proliferation status of the cells, with various proliferation kinetics and heterogeneous cell-fate choices.84 Of these compounds, the ternary complex of diphenyl pyridyl phosphine is the most promising. It exhibits the strongest early migration rates, the fastest wound closure, the highest cytotoxic efficacy, the strongest activation of TGF-β1, and the greatest upregulation of PDGF. These combined results highlight its exceptional biological and regenerative activity and justify its selection for further research, particularly in conjugation with targeted delivery strategies to improve selectivity. Experimental section Materials and instruments 4′-(2-pyridyl)-2,2':6′,2″-terpyridine,54 and silver(i) complex 2 (ref. 42) were prepared following previously published methods. All of the chemicals, including organic solvents, silver(i) trifluoromethanesulfonate, clotrimazole, diphenyl pyridyl phosphine, and 4,4′-bipyridine, were used exactly as received from commercial suppliers. 1H, 13C{1H}, 19F, and 31P NMR spectra of the silver(i) complexes were recorded at room temperature with a Bruker-Avance 400 (1H, 400.40 MHz; 13C{1H}, 100.68 MHz; 19F, 376.5 MHz; and 31P, 162.0 MHz) spectrometer. Electrospray ionization mass spectra (ESI- MS) were obtained in positive mode using an Advion compact mass spectrometer. Electronic absorption spectra were recorded using a Specord 200 Plus spectrophotometer to assess stability and lipophilicity. Elemental microanalysis was performed using a Vario Micro Cube analyzer of Elementar Analysensysteme. Synthesis Complexes 4, 6 and 8 were synthesized by mixing 4′-(2-pyridyl)-2,2':6′,2″-terpyridine (0.36 mmol; 112 mg) and one equivalent of silver(i) trifluoromethanesulfonate (93 mg) in methanol. After that, the round-bottom flasks were shielded from light, and the three reaction mixtures were stirred for 3 h at room temperature. During the stirring phase, a precipitate formed. When the secondary ligand [0.36 mmol; diphenyl pyridyl phosphine (105 mg), 4,4′-bipyridine (56 mg), and clotrimazole (124 mg)] was added, the complex redissolved in methanol, resulting in clear solutions. After filtering, the solutions were left to stand. Yellow precipitates formed after the solvent slowly evaporated. Filtration was used to collect the complexes, which were washed with hexane and vacuum-dried. 4: IR (ATR): ν = 1590, 1470, 1262, 1148, 1032, 781, and 635 cm−1. 1H NMR (DMSO-d6, 400.40 MHz): δ = 9.12 (s, 2H), 8.86 (d, 3JH,H = 4.0 Hz, 1H), 8.79 (d, 3JH,H = 4.3 Hz, 1H), 8.68 (d, 3JH,H = 7.9 Hz, 2H), 8.60 (d, 3JH,H = 4.2 Hz, 2H), 8.45 (d, 3JH,H = 7.9 Hz, 1H), 8.08 (m, 3H), 7.89 (m, 1H), 7.60 (m, 1H), 7.54–7.46 (m, 13H), and 7.32 (m, 1H) ppm. 13C{1H} NMR (CDCl3, 100.6 MHz): δ = 153.5, 152.8, 152.5, 150.5, 150.0, 149.9, 139.1, 138.2, 137.2, 134.0, 133.8, 131.3, 129.5, 129.4, 125.3, 124.9, 123.3, 122.8, 120.4 ppm. 19F NMR (CDCl3, 376.5 MHz): δ = −81.17 ppm (CF3SO3−). 31P NMR (CDCl3, 162.0 MHz): δ = 13.11 ppm. ESI-MS (positive mode, DMSO/acetone): m/z = 681.3 {AgL(PPh2Py)}+, 643.4 {2L + Na}+, 417.2 {AgL}+, 333.3 {L + Na}+ and 311.4 {L + H}+. C76H56Ag2F6N10O6P2S2: C 54.95, H 3.40, N 8.43, found C 54.73, H 3.28, N 8.18. 6: IR (ATR): ν = 1592, 1470, 1406, 1252, 1150, 1028, 780, 753, and 634 cm−1. 1H NMR (DMSO-d6, 400.40 MHz): δ = 9.00 (s, 2H), 8.87 (d, 3JH,H = 4.9 Hz, 1H), 8.73 (d, 3JH,H = 6.1 Hz, 1H), 8.63 (d, 3JH,H = 4.6 Hz, 2H), 8.60 (d, 3JH,H = 7.9 Hz, 1H), 8.46 (d, 3JH,H = 7.9 Hz, 1H), 8.10 (m, 3H), 7.85 (t, 3JH,H = 6.5 Hz, 2H), 7.61 (m, 3H) ppm. 13C{1H} NMR (DMSO-d6, 100.6 MHz): δ = 152.9, 152.8, 151.8, 150.7, 150.4, 150.2, 149.6, 144.4, 138.7, 137.9, 125.5, 125.1, 123.0, 122.4, 121.5, 119.9, and 119.1 ppm. ESI-MS (positive mode, DMSO/acetone): m/z = 643.4 {2L + Na}+, 417.2 {AgL}+, 333.3 {L + Na}+ and 311.4 {L + H}+. C31H22AgF3N6O3S: C 51.47, H 3.07, N 11.62, found C 51.23, H 2.89, N 11.39. 8: IR (ATR): ν = 1593, 1471, 1407, 1259, 1152, 1028, 776 and 633 cm−1. 1H NMR (DMSO-d6, 400.40 MHz): δ = 9.06 (s, 2H), 8.87 (d, 3JH,H = 5.0 Hz, 1H), 8.69 (d, 3JH,H = 4.0 Hz, 2H), 8.65 (d, 3JH,H = 7.9 Hz, 2H), 8.46 (d, 3JH,H = 8.4 Hz, 1H), 8.10 (t, 3JH,H = 7.8 Hz, 4JH,H = 1.5 Hz, 3H), 7.81 (s, 2H), 7.61 (m, 3H), 7.56–7.52 (m, 4H), 7.44 (m, 13H), 1.95 (s, 2H), 7.09 (m, 9H), and 6.93 (d, 3JH,H = 8.1 Hz, 4JH,H = 1.5 Hz, 2H) ppm. 13C{1H} NMR (CDCl3, 100.6 MHz): δ = 153.3, 152.8, 152.3, 150.3, 150.1, 149.3, 140.4, 139.8, 139.2, 138.6, 137.9, 134.5, 132.3, 130.8, 130.5, 129.5, 128.8, 128.4, 128.3, 127.7, 125.4, 125.0, 122.7, 122.3, 122.2, 122.1, 119.4, 119.1 and 75.3 ppm. ESI-MS (positive mode, DMSO/acetone): m/z = 643.4 {2L + Na}+, 417.2 {AgL}+, 333.3 {L + Na}+ and 311.4 {L + H}+. C64H45Ag2ClF6N10O6S2: C 51.96, H 3.07, N 9.47, found C 51.76, H 2.84, N 9.29. Cell viability assay Cell lines and cell culture Two distinct human skin models were examined in this study: the main dermal fibroblast normal human neonate cell line, HDFn, and the human epithelial skin malignant melanoma cell line, A375. The American Type Culture Collection (ATCC, USA) provided both cell lines. Dulbecco's Modified Eagle Medium with high glucose was the standard culture medium for the A375 cell line, whereas Basal Fibroblast medium was used for the HDFn cell line. 10% foetal bovine serum (FBS), 2 mM l-glutamine, and a 1% antibiotic-antimycotic cocktail make up the entire medium. The standard conditions for cell culture were 37 °C, 80% humidity, and 5% CO2. The cells were sub-cultured by washing them three times with Dulbecco's Phosphate Buffered Saline, trypsinizing them with 0.5% (w/v) trypsin–EDTA, resusoending them in complete medium, centrifuging, and counting. Determination of the safe dose on the proliferation of skin cell lines by the MTT assay The cytotoxicity was investigated in both A375 and HDFn cell lines using the MTT assay.85 Each well of a 96-well cell culture plate received an aliquot of 180 µL of cell suspension (5 × 103 cells), which was then cultured in complete medium under standard culture conditions overnight. After dissolving 1–8 in DMSO, each sample was serially diluted to concentrations ranging from 3.125 to 100 µg mL−1. A 24-hour incubation period was given to the treated cell lines. After discarding the medium, each well received 40 µL of MTT (5 mg mL−1) for 4 h. Next, acidified isopropanol (180 µL per well) was used to dissolve the formazan crystals. Finally, the optical density of the developed deep-blue colour was measured at 570 nm using an ELISA microplate reader (FLUOstar OPTIMA, BMG LABTECH, Germany). Wound healing parameters Scratch assay In 6-well cell culture plates, each cell line, A375 and HDFn cells were cultured at a density of 5 × 105 per 2 mL in each well. The cells were allowed to form a complete monolayer before wounding. Using a 10-µL sterile pipette tip, uniform scratches were made in each well under continuous pressure. Each well was washed twice with phosphate-buffered saline (PBS) to remove cell debris. In each cell line, each compound was adjusted to the corresponding IC10. The area and distances of the scratches were measured using an inverted microscope (BDS400, Drawell International Technology Limited, China) fitted with an Olympus SC180 camera (Olympus, Japan) and CellSens® software (Olympus, Japan). The scratch areas and distances were measured at 0, 6, and 24 h until complete closure.86 Transforming growth factor Beta-1 (TGF-β1) protein expression Each well of an 8-well chamber slide contained 1 × 104 cells from each cell line. For 24 h, the cells were exposed to the corresponding IC10 of each complex (2, 4, and 6–8). After incubation, the cells were fixed with 4% paraformaldehyde, washed with PBS, blocked with 2% bovine serum albumin, and then labelled with TGF-β1 rabbit polyclonal antibody (# PA1-29032, Invitrogen, USA) at a dilution of 1 : 100. Next, the cells were washed extensively with PBS, labelled with the secondary antibody Alexa Fluor 488 Goat anti-Rabbit IgG (H + L) A-11008, Invitrogen, USA at a dilution of 1 : 200 in the dark, and finally washed three times with PBS. The slides were allowed to air dry in the dark before being counterstained with a glycerol based mounting medium containing DAPI (4′,6-diamidino-2-phenylindole) as an antifade and nuclear counterstain. The protein was visualized by the fluorescent microscope Axio Imager Z2 (Zeiss, Germany) with the following filter settings: DAPI (Excitation, 335–383 nm and emission 420–470 nm) and HE BFP/GFP/HcRed (Excitation 350–390, 460–488, and 567–602 nm, as well as emission 395, 495, and 610 nm). Using the Zen-11 Blue edition software, the fluorescence intensity was measured. Human platelet-derived growth factor (PDGF-BB) protein detection Each cell line was cultivated in 12-well cell culture plates with 7.5 × 105 cells per well. For 24 h, the cells were exposed to complexes (2, 4, and 6–8) at concentrations to half of their IC10 values. After incubation, the cell culture supernatant were collected and centrifuged at 10 000 rpm. With the aid of an ELISA Kit (E-EL-H1577, Elabscience), the PDGF-BB protein was quantified in the samples using the sandwich ELISA technique according to the manufacturer's protocol. Flow cytometry analysis of cell cycle progression Both cell lines, A375 and HDFn, were grown in 6-well plates (5 × 105 cells per well) and allowed to attach overnight. The next day, the cells were exposed to the tested compounds at the concentration that matched their respective IC25 values. The cells were collected and washed with PBS following a 24-hour incubation period. Following the protocol, the cells were stained using the BD CycletestTM Plus DNA Reagent Kit (Cat. No. 340242, BD, USA) and fixed with ice-cold 4% paraformaldehyde. The cells were then analysed by the Cytoflex flow cytometer and the CytExpert software (Beckman Coulter, Inc., California, USA). Antimicrobial analysis The antimicrobial activity of 2 and 6–8 was determined by the broth dilution method.87 Bacteria and yeast strains were obtained from the American Type Culture Collection, USA. The organisms used are Gram-positive bacteria: Bacillus subtilis (ATCC 6633), Staphylococcus epidermidis (ATCC 12228), Micrococcus luteus (ATCC 4698), and Staphylococcus aureus (ATCC 6538). The Gram-negative bacterium was Pseudomonas aeruginosa (ATCC 27853). The pathogenic yeast was Candida albicans (ATCC 10231). The specifics and procedures used to assess antimicrobial properties of the complexes were reported elsewhere.81 Author contributions Mahmoud Abo-Elfadl: conceptualization, investigation, validation, resources, formal analysis, software, writing – original draft, writing – review & editing. Mohamed Mohamed: methodology. Rabaa Khaled: methodology. Krzysztof Radacki: methodology, investigation, resources. Gamal Mostafa, writing – review and editing, resources. Essam Ali, writing – review & editing, resources. Ola Shehab: investigation, writing – review & editing. Ahmed Mansour: conceptualization, investigation, validation, resources, formal analysis, software, writing – original draft, writing – review & editing. Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Supplementary Material